Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin Powder in Craniotomy for Wound Infection Prevention
NCT04917627Phase 4Unknown
- Sponsor
- Hamad General Hospital
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vancomycin in surgical site infection (SSI) (2 arms), sponsored by Hamad General Hospital. Primary endpoint: Rate of wound infection at 24 months. Status: unknown.
02
Drugs
vancomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT04917627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917627.